Peter Reichardt, MD, PhD, on GIST: Adjuvant Imatinib for High-Risk Disease
ASCO20 Virtual Scientific ProgramPeter Reichardt, MD, PhD, of Helios Klinikum Berlin-Buch, discusses the 10-year survival analysis of 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumor. The study found that about 50% of deaths can be avoided with longer imatinib treatment (Abstract 11503).
Related Videos
Thierry André, MD, on Colorectal Cancer: Pembrolizumab vs Chemotherapy for Metastatic Disease
Thierry André, MD, of Hôpital Saint-Antoine, discusses the phase III results from KEYNOTE-177, which showed that, compared with standard chemotherapy of FOLFOX or FOLFIRI, p...
Lourdes Gil Deza on Caring for Transgender Patients With Cancer
Professor Lourdes Gil Deza, of the Instituto Oncológico Henry Moore, Buenos Aires, discusses her findings on the shortcomings of medical training when it comes to treating tr...
Howard A. Burris III, MD, FACP, FASCO, on the ASCO20 Virtual Scientific Program: After Action Report
Howard A. Burris III, MD, FACP, FASCO, Immediate Past President of ASCO and current Society Board Chair, talks about how the meeting went, with its record-breaking attendance...
Neal D. Shore, MD, on Prostate Cancer: Relugolix vs Leuprolide for Advanced Disease
Neal D. Shore, MD, of the Carolina Urologic Research Center, discusses phase III results of the HERO study, which showed relugolix achieved castration as early as day 4 and w...
Richard L. Schilsky, MD, on This Year’s Practice-Changing Findings
Richard L. Schilsky, MD, Chief Medical Officer of ASCO, talks about some of the most important and practice-changing findings presented this year at...
